RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) appointed Hugh Rogers to its board.
Mr. Rogers has extensive corporate finance and restructuring experience through his work with various TSX-V listed issuers and private companies, including his most recent roles as CEO of Coronado Resources since March 2015 and VP corporate finance at 3D Signatures since April 2015.
“Hugh’s addition to the board is another step forward in the company’s transformation that we began in 2016,” president and CEO, Lee Buckler, said in a statement. “RepliCel is poised for an exciting year building on our existing momentum and near-term milestones.”
Mr. Rogers said that with data on multiple trials expected early this year and a recently streamlined capital structure, RepliCel has started off 2017 in a very attractive position.
